RNS Number: 9200D Allied Minds PLC 28 June 2019

28 June 2019

Allied Minds plc (the "Company")

Results of Annual General Meeting

The Annual General Meeting of Allied Minds plc was held earlier today. All of the resolutions proposed at the Annual General Meeting were duly passed by the shareholders on a poll.

The results of the poll, incorporating the proxy votes lodged in advance of the meeting, are set out below.

Resolutions	For	%	Against	%	Withheld	Total lodged			
1. To receive the Company's Annual Report and Accounts for the financial year ended 31 December 2018.	170,365,941	99.36	1,104,035	0.64	784	171,469,976			
2. To approve the Directors' Remuneration Report (excluding the Directors' Remuneration Policy) for the year ended 31 December 2018.	107,255,825	80.84	25,426,802	19.16	38,788,134	132,682,627			
3. To approve the Directors' Remuneration Policy.	129,448,525	85.13	22,612,862	14.87	19,409,374	152,061,387			
4. To re-appoint KPMG LLP as auditor of the Company.	169,856,531	100.00	5,455	0.00	1,608,774	169,861,986			
5. To authorise the Audit Committee to determine the auditor's remuneration.	171,464,881	100.00	2,096	0.00	3,784	171,466,977			
6. To re-elect Mr. Peter Dolan as a Director of the Company.	Resolution withdrawn.								
7. To re-elect Ms. Jill Smith as a Director of the Company.	Resolution withdrawn.								
8. To re-elect Mr.									

Harry Rein as a Director of the Company.	157,115,389	91.63	14,349,488	8.37	5,884	171,464,877			
9. To re-elect Mr. Jeffrey Rohr as a Director of the Company.	157,113,528	91.63	14,351,348	8.37	5,884	171,464,876			
10. To re-elect Mr. Kevin Sharer as a Director of the Company.	Resolution withdrawn.								
11. To elect Mr. Fritz Foley as a Director of the Company.	157,144,844	91.65	14,320,033	8.35	5,884	171,464,877			
12. To authorise the Directors to allot shares under section 551 of the Companies Act 2006.	163,733,878	95.49	7,728,709	4.51	8,174	171,462,587			
13. To disapply statutory pre-emption rights.	163,732,359	95.49	7,732,415	4.51	5,987	171,464,774			
14. In addition to the authority granted under Resolution 13, to disapply statutory pre-emption rights solely in relation to acquisitions and specified capital investments.	162,647,258	94.86	8,821,115	5.14	2,387	171,468,373			
15. To authorise the Company to make political donations and incur political expenditure.	171,448,121	99.99	19,040	0.01	3,600	171,467,161			
16. To authorise the Company to make market purchases of its own shares.	170,377,621	99.36	1,092,372	0.64	767	171,469,993			
17. To authorise the Company to hold general meetings on not less than 14 clear days' notice.	171,366,885	99.94	103,859	0.06	17	171,470,744			

While all resolutions were passed at the annual general meeting, we were disappointed that there was a significant minority of votes against the advisory resolution on the Remuneration Report. Overall, the Remuneration Committee considers that the remuneration structure continues to be broadly appropriate and aligned with the Company strategy while balancing typical UK-listed market practice with US practice in our market for talent. In line with our commitment to maintaining an open and transparent dialogue with shareholders, we will be consulting with all major shareholders in the second half of 2019 to gain their input in this review. We will also consult further on the concerns raised on this resolution and in

accordance with the UK Corporate Governance Code, we will publish an update on that engagement within six months of the AGM.

Notes:

- 1. A vote "Withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.
- 2. As at 26 June 2019, the number of issued shares in the Company was 240,703,856 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.
- 3. The full text of the resolutions may be found in the Notice of the Annual General Meeting, copies of which are available on both the Company's website www.alliedminds.com and on the National Storage Mechanism.
- 4. In accordance with Listing Rule 9.6.1, a copy of the resolutions, other than those concerning ordinary business has been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.morningstar.co.uk/uk/NSM.
- 5. Jill Smith resigned from the Company with effect from 10 June 2019. Therefore, with the consent of the meeting, the resolution regarding her re-election was not proposed.
- 6. Peter Dolan resigned from the Company with effect from the close of the AGM on 28 June 2019. Therefore, with the consent of the meeting, the resolution regarding his re-election was not proposed.
- 7. Kevin Sharer resigned from the Company with effect from the close of the AGM on 28 June 2019. Therefore, with the consent of the meeting, the resolution regarding his re-election was not proposed.

About Allied Minds

Allied Minds plc is an IP commercialisation company focused on early stage company development within the technology and life science sectors. With origination relationships that span US federal laboratories, universities, and leading US corporations, Allied Minds historically created, and now operates and funds, a portfolio of companies to generate long-term value for its investors and stakeholders. Based in Boston, Allied Minds supports its businesses with capital, management, expertise and shared services. For more information, please visit www.alliedminds.com.

For more information, please contact:

Allied Minds plc +44 7771 872 922

Neil Pizey, Head of Corporate

Development

Hamiltonia 44 7771 872 922

IR@alliedminds.com

FTI Consulting +44 20 3727 1000

Ben Atwell / Brett Pollard

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns.com.

END